6alpha,9alpha-Difluoro-11beta-hydroxy-16alpha-methyl-2',3,4'-trioxo-17alpha-spiro(androsta-1,4-diene-17,5'-(1,3)oxathiolane)(CAS: 219719-95-6)

This compound must comply with various regulatory guidelines including GHS classification, REACH regulations in the EU, FDA requirements in the USA, and EPA guidelines in the USA. Specific classification and handling instructions are based on its potential hazards, such as flammability, reactivity, and environmental impact.

Alternatives include using isomers or analogs, such as 6alpha,9alpha-Difluoro-11beta-hydroxy-16alpha-methyl-2',3-dioxo-17alpha-spiro(androsta-1,4-diene-17,5'-(1,3)oxathiolane), which can serve as effective substitutes in many synthetic pathways. Common alternative reagents may include fluorine-containing reagents like trifluoromethanesulfonic acid for fluoroalkylation reactions.

The market trend for this compound shows increasing interest in its applications in pharmaceuticals and research due to its unique structural features. Research is focusing on its potential as an intermediate in steroid synthesis and as a bioactive compound. Market demand is driven by growing investment in drug discovery and development, particularly in hormone-related therapies.

Waste containing this compound should be collected and stored in appropriate, leak-proof containers. It should then be disposed of via incineration or professional waste disposal services that adhere to environmental protection standards. Care should be taken to ensure that the waste does not contaminate the environment, and all disposal methods should comply with local and international regulations such as those outlined in the Basel Convention.